- Home
- GSIW vs NERV Comparison
GSIW vs NERV Comparison
Compare GSIW & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- NERV
- Stock Information
- Founded
- GSIW 2016
- NERV 2007
- Country
- GSIW Hong Kong
- NERV United States
- Employees
- GSIW N/A
- NERV N/A
- Industry
- GSIW
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- GSIW
- NERV Health Care
- Exchange
- GSIW Nasdaq
- NERV Nasdaq
- Market Cap
- GSIW 8.3M
- NERV 12.4M
- IPO Year
- GSIW 2023
- NERV 2014
- Fundamental
- Price
- GSIW $0.44
- NERV $1.61
- Analyst Decision
- GSIW
- NERV Hold
- Analyst Count
- GSIW 0
- NERV 1
- Target Price
- GSIW N/A
- NERV $5.00
- AVG Volume (30 Days)
- GSIW 45.1K
- NERV 7.7K
- Earning Date
- GSIW 12-31-2024
- NERV 05-20-2025
- Dividend Yield
- GSIW N/A
- NERV N/A
- EPS Growth
- GSIW N/A
- NERV N/A
- EPS
- GSIW N/A
- NERV 0.19
- Revenue
- GSIW $1,313,795.00
- NERV N/A
- Revenue This Year
- GSIW N/A
- NERV N/A
- Revenue Next Year
- GSIW N/A
- NERV N/A
- P/E Ratio
- GSIW N/A
- NERV $8.42
- Revenue Growth
- GSIW N/A
- NERV N/A
- 52 Week Low
- GSIW $0.35
- NERV $1.15
- 52 Week High
- GSIW $12.30
- NERV $3.69
- Technical
- Relative Strength Index (RSI)
- GSIW 52.90
- NERV 46.58
- Support Level
- GSIW $0.38
- NERV $1.65
- Resistance Level
- GSIW $0.44
- NERV $1.75
- Average True Range (ATR)
- GSIW 0.03
- NERV 0.09
- MACD
- GSIW 0.01
- NERV -0.00
- Stochastic Oscillator
- GSIW 85.11
- NERV 31.03
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.